Key result
Moderate or severe HIV-associated autonomic neuropathy predicted a composite of death, cardiovascular events, or severe organ disease compared to no or mild neuropathy (HR 3.85; 95% CI 1.61-9.20).
Why the study?
HIV-associated autonomic neuropathy is common, but its clinical effect and whether it predicts adverse clinical outcomes remained unclear.
Does moderate or severe autonomic neuropathy predict death, cardiovascular events, or severe organ disease in people living with HIV?
Cohort (n=111)
No
Does moderate or severe autonomic neuropathy predict death, cardiovascular events, or severe organ disease in people living with HIV?
Moderate to severe autonomic neuropathy in people living with HIV is associated with a nearly 4-fold increased risk of death, major cardiovascular events, or severe organ disease.
HIV autonomic neuropathy may flag higher-risk patients; hypothesis-generating for monitoring pending prospective validation.
Background and Objectives: HIV-associated autonomic neuropathy (HIV-AN) is common; however, its clinical effect is unclear. Previously, it was shown that the composite autonomic severity score is associated with markers of morbidity such as the Veterans Affair Cohort Study index. In addition, it is known that cardiovascular autonomic neuropathy due to diabetes is associated with poor cardiovascular outcomes. This study aimed to evaluate whether HIV-AN is predictive of important adverse clinical outcomes. Method: The electronic medical records of HIV-infected participants who underwent autonomic function tests at the Mount Sinai Hospital between April 2011 and August 2012 were reviewed. The cohort was stratified into those who had no or mild autonomic neuropathy (HIV-AN [-], CASS ≤3) and those with moderate or severe autonomic neuropathy (HIV-AN [+], CASS >3). The primary outcome was a composite of the incidence of death from any cause, new major cardiovascular or cerebrovascular event, or development of severe renal or hepatic disease. Time-to-event analysis was performed using Kaplan-Meier analysis and multivariate Cox proportional hazards regression models. Results: One hundred eleven of 114 participants had follow-up data (median follow-up for HIV-AN (-) was 94.00 months, and HIV-AN (+) was 81.29 months) and were included in the analysis. Participants were followed until March 1, 2020. The HIV-AN (+) group (N = 42) was significantly associated with the presence of hypertension, higher HIV-1 viral load, and more abnormal liver function. Seventeen (40.48%) events occurred in the HIV-AN (+) group, and 11 (15.94%) occurred in the HIV-AN (-) group. Six (14.29%) cardiac events occurred in the HIV-AN (+) group, whereas 1 (1.45%) occurred in the HIV-AN (-) group. The other subgroups of the composite outcome had a similar trend. The adjusted Cox proportional hazards model showed that the presence of HIV-AN predicted our composite outcome (HR 3.85, CI 1.61-9.20). Discussion: These findings suggest that HIV-AN is associated with the development of severe morbidity and mortality in people living with HIV. People living with HIV with autonomic neuropathy may benefit from closer cardiac, renal, and hepatic surveillance.
No takes yet. Share an insight, caveat, or question.
Kwon et al. (2023) conducted a cohort in HIV-associated autonomic neuropathy (n=111). Moderate or severe autonomic neuropathy (HIV-AN [+]) vs. No or mild autonomic neuropathy (HIV-AN [-]) was evaluated on Composite of the incidence of death from any cause, new major cardiovascular or cerebrovascular event, or development of severe renal or hepatic disease (HR 3.85, 95% CI 1.61-9.20). Moderate or severe HIV-associated autonomic neuropathy predicted a composite of death, cardiovascular events, or severe organ disease compared to no or mild neuropathy (HR 3.85; 95% CI 1.61-9.20).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: